Platinum-Based Neoadjuvant Chemotherapy versus Primary Surgery in Ovarian Carcinoma International Federation of Gynecology and Obstetrics Stages IIIc and IV: A Systematic Review and Meta-Analysis-Reference-Cited by-同舟云学术

Platinum-Based Neoadjuvant Chemotherapy versus Primary Surgery in Ovarian Carcinoma International Federation of Gynecology and Obstetrics Stages IIIc and IV: A Systematic Review and Meta-Analysis

Published:2017-12-21 Issue:3 Volume:83 Page:209-219
ISSN:0378-7346
Container-title:Gynecologic and Obstetric Investigation
language:en
Short-container-title:Gynecol Obstet Invest

Author:

Xiao Yunyun,Xie Shuang,Zhang Ningning,Wang Jiao,Lv Chao,Guo Jiao,Yang Qing

Publisher

S. Karger AG

Subject

Obstetrics and Gynaecology,Reproductive Medicine

Reference35 articles.

1. Siesto G, Cavina R, Romano F, Vitobello D: Primary debulking surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a propensity-matched analysis. Am J Clin Oncol 2016, Epub ahead of print.

2. Stuart GC, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J, Marth C, Thigpen T, Trimble E; Participants of 4th Ovarian Cancer Consensus Conference (OCCC); Gynecologic Cancer Intergroup: 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the fourth ovarian cancer consensus conference. Int J Gynecol Cancer 2011; 21: 750–755.

3. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M, Dobbs S, Essapen S, Twigg J, Herod J, McCluggage G, Parmar M, Swart AM: Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 2015; 386: 249–257.

4. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group: Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363: 943–953.

5. Bian C, Yao K, Li L, Yi T, Zhao X: Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer. Arch Gynecol Obstet 2016; 293: 163–168.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Primary Cytoreductive Surgery Versus Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: the Primary Cytoreductive Surgery is Better Than Neoadjuvant Chemotherapy in Platinum-resistant Patients;2024-07-23

2. Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction;Diagnostics;2022-04-14

3. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer;Cochrane Database of Systematic Reviews;2021-07-30

4. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer;Cochrane Database of Systematic Reviews;2021-02-05

5. Effect of tumor burden and radical surgery on survival difference between upfront, early interval or delayed cytoreductive surgery in ovarian cancer;Journal of Gynecologic Oncology;2021